Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539617 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00539617 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 7 participants.
The verdict
NCT00539617, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery.
Interventions
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG 5-fluorouracil
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-10-05 |
| Est. Completion | 2011-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539617
The ClinicalTrials.gov registry entry for NCT00539617 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Leucovorin is the first listed.
NCT00539617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00539617 about?
NCT00539617 is a clinical study titled "Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery". The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery.
What is the current status of trial NCT00539617?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-10-05. Estimated completion is 2011-05-12.
What interventions are being tested in trial NCT00539617?
The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), 5-fluorouracil (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00539617?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.